Serum miRNA profiling is especially exciting given that it is accessible in a non-invasive manner, and it may be possible to establish a diagnostic serum miRNA panel that would reduce the need for prostate biopsies in patients with elevated PSA levels, some of whom ultimately will not have prostate cancer. The gene discussed is KLK3; the disease is prostate cancer.